Simvastatin to Prevent SCI-Induced Bone Loss

Exclusion Criteria

• •\- have any simvastatin contraindications including:
• •drug allergy,
• •active liver disease,
• •renal dysfunction,
• •concurrent use of drugs that cause myopathy or increase the risk of myopathy with simvastatin therapy (gemfibrozil, niacin, cyclosporine, danazol, amiodarone, dronedarone, ranolazine, calcium channel blockers, colchicine), strong CYP34A inhibitors (itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat-containing products), low plasma cholesterol levels,
• •uncontrolled or poorly controlled diabetes,
• •unstable anti-coagulation treatment,
• •taking a statin in the preceding 12 months,
• •metabolic bone disease, thyroid disorder,
• •history of bilateral oophorectomy,
• •current use of medications potentially affecting bone health including bisphosphonates, androgenic steroids, estrogenic steroids, anti-epileptics, lithium glucocorticoid use for more than 3 months,
• •have received inhaled glucocorticoids in the past 12 months,
• •pregnant or lactating women,
• •women of childbearing potential who are unwilling or unable to use a reliable form of contraception.